ImaCor of Garden City, NY has unveiled its new Zura EVO ultrasound that’s intended for use with the company’s ClariTEE transesophageal echocardiography probe. The ClariTEE is intended for continuous hemodynamic monitoring in acute care patients for up to 72 hours.
The EVO is a miniaturized version of the original Zura system featuring a large touchscreen, the latest ImaCor software, and an “enhanced hTEE measurement package specific to area changes of the superior vena cava, and the right and left ventricles of the heart,” according to the firm.
From the announcement:
hTEE technology includes a purpose-built ultrasound imaging system consisting of the ClariTEE probe and Zura™ platform. The ClariTEE has a unique piezoelectric design with a highly efficient structure to provide quality imaging at 7 MHz with 15 cm penetration. Featuring optimized signal processing, thermal management, and Adaptaflex™, the ClariTEE probe on the Zura system provides real-time visualization of the heart for up to 72 hours indwelling. This capability makes hTEE technology ideal for hemodynamic management of critically ill or injured patients over a period of time.
Press release: ImaCor Introduces the Zura EVO™
